Valuation: AstraZeneca Pharma India Limited

Market Cap 148B 1.53B 1.37B 1.28B 1.16B 2.19B 2.2B 15.41B 6B 75.45B 5.76B 5.64B 243B P/E 2025
186x
P/E 2026 103x
Enterprise Value 144B 1.5B 1.34B 1.25B 1.13B 2.14B 2.15B 15.06B 5.86B 73.73B 5.63B 5.51B 237B EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
18.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day-2.02%
1 week-9.16%
Current month-4.48%
1 month-14.90%
3 months-28.90%
6 months-24.51%
Current year-34.56%
1 week 5,882
Extreme 5882
6,355
1 month 5,882
Extreme 5882
6,994
Current year 5,882
Extreme 5882
9,220
1 year 5,882
Extreme 5882
9,849.5
3 years 4,475
Extreme 4475
10,691
5 years 2,445.7
Extreme 2445.7
10,691
10 years 880.2
Extreme 880.2
10,691
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Compliance Officer - 23/02/2026
Chief Tech/Sci/R&D Officer - 03/03/2025
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 52 30/09/2024
Director/Board Member - 09/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
-2.02%-9.16% - - 1.57B
+0.02%-3.41%+36.11%+115.09% 1,019B
-1.21%-6.74%+34.08%+62.64% 617B
+1.12%+0.54%+13.62%+79.94% 464B
-3.30%-6.21%+56.45%+36.58% 356B
+0.93%-3.16%+21.65%+43.02% 333B
+0.12%-2.77%+10.70%+32.97% 267B
-0.89%-6.28%-7.00%+8.01% 244B
-0.01%-2.81%+35.28%+51.82% 218B
-0.08%-4.17%+28.34%+93.51% 179B
Average -0.89%-3.54%+25.47%+58.17% 410.8B
Weighted average by Cap. -0.51%-3.54%+28.50%+70.11%

Financials

2025 2026
Net sales 17.16B 178M 159M 148M 135M 254M 256M 1.79B 696M 8.76B 669M 655M 28.16B 22.76B 236M 211M 196M 179M 337M 339M 2.37B 923M 11.61B 887M 868M 37.33B
Net income 1.16B 12.02M 10.72M 9.99M 9.09M 17.12M 17.24M 121M 46.96M 591M 45.11M 44.14M 1.9B 1.88B 19.47M 17.37M 16.18M 14.73M 27.73M 27.94M 196M 76.08M 957M 73.09M 71.52M 3.08B
Net Debt -5B -51.96M -46.35M -43.18M -39.3M -74.01M -74.56M -522M -203M -2.55B -195M -191M -8.21B -3.37B -35M -31.22M -29.09M -26.47M -49.85M -50.22M -351M -137M -1.72B -131M -129M -5.53B
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
05/10/26 ₹5,909.00 -2.02% 6,412
01/10/26 ₹6,031.00 -2.51% 11,473
30/09/26 ₹6,186.00 -1.10% 56,730
29/09/26 ₹6,254.50 -0.41% 8,506
28/09/26 ₹6,280.00 -3.46% 10,121
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A